X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged

Content Team by Content Team
8th July 2022
in Manufacturing, Middle East and South Asia, News
AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged

The standard response to any poor performance is to blame the supply chain, which has almost attained the status of a joke. However, it is now one of a serious group of interconnected economic headwinds that also includes the conflict in the Ukraine, COVID lockdowns in China, inflation, and the consequent increase in operational costs. Some businesses, particularly in Europe, are alerting investors to possible ramifications.

According to a European Big Pharma analysis from ODDO BHF analysts, AstraZeneca and GSK look to have weathered the external headwinds more effectively than most, with second quarter earnings results due in the coming weeks. For Roche, though, not so much. According to the team, AZ and GSK each ended the second quarter 7% higher than they had begun, while Roche had a 13% decline in market value.

As per ODDO, the pharmaceutical industry in Europe was generally less vulnerable to the adversities than other sectors. Companies in Stoxx HealthCare decreased by 5%, while those in Stoxx Europe 600 dropped overall by 10.5%. The analysts also predict favourable implications from the foreign currency market for Sanofi and Novo Nordisk.

Many businesses have issued warnings about the challenges the industry has been facing during the past few months. Executives from Bayer, GSK, and other firms concentrated on how inflation was affecting their profit margins in March. In May, Merck KGaA issued a warning to shareholders, saying that increasing volatility and uncertainty would cause the company to change its forecasts for the fiscal year 2022.

Markets then experienced a rumble two weeks ago when UCB announced that headwinds had led the business to lower its profit margin projection for the year from 26-27% to 21-22%. However, ODDO claimed that it hasn’t encountered the same gloom and doom in its regular conversations with pharma executives.

While UCB raised the alarm on the worsening macroeconomic environment, ODDO said that it has not noticed any companies adopting an alarmist tone in advance of the Q2 results.

Regarding the near future, ODDO stated that it is considering GSK’s reorganisation and anticipates an IPO for its consumer business Haleon on July 18, enabling the new GSK to concentrate on specialty pharma. Next, it will be Novartis’ chance to decide whether to sell, split, or keep its generics division, Sandoz. In a complex macroeconomic situation, the analysts said, they consider that the European pharma space should therefore carry on playing its defensive role, still preferring AstraZeneca and Sanofi.

Previous Post

Paxlovid Allowed By FDA To Sell At Certified Pharmacies

Next Post

Pfizer And Touchlight Enter Into A Patent Collaboration

Related Posts

Lonza To Construct $518mn Fill-Finish Plant In Switzerland
Manufacturing

Lonza To Construct $518mn Fill-Finish Plant In Switzerland

8th July 2022
Pfizer And Touchlight Enter Into A Patent Collaboration
Manufacturing

Pfizer And Touchlight Enter Into A Patent Collaboration

8th July 2022
Paxlovid Allowed By FDA To Sell At Certified Pharmacies
Manufacturing

Paxlovid Allowed By FDA To Sell At Certified Pharmacies

8th July 2022
Deloitte Believes Mature R&D Firms Reap Enterprise Value
Manufacturing

Deloitte Believes Mature R&D Firms Reap Enterprise Value

7th July 2022
Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

Singapore Authorises New Ovarian Cancer Treatment By GSK

5th July 2022
Next Post
Pfizer And Touchlight Enter Into A Patent Collaboration

Pfizer And Touchlight Enter Into A Patent Collaboration

Latest News

Lonza To Construct $518mn Fill-Finish Plant In Switzerland
Manufacturing

Lonza To Construct $518mn Fill-Finish Plant In Switzerland

8th July 2022
Pfizer And Touchlight Enter Into A Patent Collaboration
Manufacturing

Pfizer And Touchlight Enter Into A Patent Collaboration

8th July 2022
AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged
Manufacturing

AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged

8th July 2022
Paxlovid Allowed By FDA To Sell At Certified Pharmacies
Manufacturing

Paxlovid Allowed By FDA To Sell At Certified Pharmacies

8th July 2022
Deloitte Believes Mature R&D Firms Reap Enterprise Value
Manufacturing

Deloitte Believes Mature R&D Firms Reap Enterprise Value

7th July 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In